The occurrence of ligand-independent, constitutively active androgen receptor splice variants in castration–resistant prostate cancer provides a conceptually simple explanation for the development of resistance to prostate cancer therapies that target the ligand-binding domain. This evidence concerns the gene AR and prostate cancer.